ArticleBMC gastroenterology2025
Combining endoscopic variceal ligation and omeprazole sodium in treating upper gastrointestinal hemorrhage combined with liver cirrhosis.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparison of Outcomes From Sequential Endoscopic Therapy in 60 Patients With Cirrhosis and Esophagogastric Varices Treated at a Provincial and a Tertiary District Hospital.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCirrhosis, a common chronic liver disease, leads to portal hypertension and complications like ascites and variceal bleeding. Endoscopic variceal ligation (EVL) is the preferred treatment for variceal bleeding. Post-EVL rebleeding due to mucosal irritation from gastric reflux significantly impacts patient prognosis. Omeprazole is an acid-suppressing medication to reduce mucosal damage and improve hemostasis. However, the effect of EVL combined with omeprazole in the treatment of esophageal variceal hemorrhage in cirrhosis remains exploring. Therefore, the present study aims to investigate the value of EVL + omeprazole in treating upper gastrointestinal hemorrhage combined with liver cirrhosis.
methodsOne hundred patients with cirrhosis combined with upper gastrointestinal bleeding (January 2019-December 2022) were included as study subjects. Patients were categorized into observation (50 cases, omeprazole + endoscopic ligation) and control (50 cases, endoscopic ligation) groups. Clinical effects, hemostatic effects, portal venous blood flow, and stress indicators between the two groups were compared.
resultsThe blood transfusion volume, hospitalization time, hemostasis time and rebleeding rate of the observation group were statistically lower than control (P < 0.05). The portal vein blood flow and splenic vein blood flow in both groups after treatment were significantly lower than those before treatment (P < 0.05). The total effective rate of observation group was significantly higher than control (94.0% vs. 80.0%, P < 0.05). Also, the expression of serum amyloid A (SAA), IL-6, procalcitonin (PCT), cortisol (Cor), prostaglandin E2 (PGE2) and C-reactive protein (CRP) in observation group were significantly lower than control (P < 0.05).
conclusionThe combination of EVL and omeprazole effectively manages esophagogastric variceal hemorrhage in cirrhotic patients, enhancing hemostasis, reducing rebleeding, and improving portal hemodynamics.
trial registrationNot applicable. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.